OSCAR VILLAVICENCIO-CARRISOZA

Dr. OSCAR VILLAVICENCIO-CARRISOZA

inmunobioquimica, Instituto Nacional de Perinatología, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
MVMaría Yolotzin Valdespino‐Vázquez
María Yolotzin Valdespino‐Vázquez
CHCecilia A. Helguera‐Repetto
Cecilia A. Helguera‐Repetto
MLMoises León‐Juárez
Moises León‐Juárez
OVOSCAR VILLAVICENCIO-CARRISOZA
OSCAR VILLAVICENCIO-CARRISOZA
Arturo Flores-PliegoArturo Flores-Pliego
Arturo Flores-Pliego
CIClaudine Irles
Claudine Irles

11 September 2020 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
AHAddy Cecilia Helguera-Repetto
Addy Cecilia Helguera-Repetto
MSMaría Dolores Soto-Ramírez
María Dolores Soto-Ramírez
OVOSCAR VILLAVICENCIO-CARRISOZA
OSCAR VILLAVICENCIO-CARRISOZA
SYSamantha Yong-Mendoza
Samantha Yong-Mendoza
AYAngélica Yong-Mendoza
Angélica Yong-Mendoza
CIClaudine Irles
Claudine Irles
Neonatal sepsis remains difficult to diagnose due to its non-specific signs and symptoms. Traditional scoring systems help to discriminate between septic or not patients, but they do not consider every single patient particularity. Thus, the purpose of this study was to develop an early- and late-onset neonatal sepsis diagnosis model, based on clinical maternal and neonatal data from electronic records, at the time of clinical suspicion. A predictive model was obtained by training and validating an artificial Neural Networks (ANN) algorithm with a balanced dataset consisting of preterm and term non-septic or septic neonates (early- and late-onset), with negative and positive culture results, respectively, using 25 maternal and neonatal features. The outcome of the model was sepsis or not. The performance measures of the model, evaluated with an independent dataset, outperformed physician's diagnosis using the same features based on traditional scoring systems, with a 93.3% sensitivity, an 80.0% specificity, a 94.4% AUROC, and a regression coefficient of 0.974 between actual and simulated results. The model also performed well-relative to the state-of-the-art methods using similar maternal/neonatal variables. The top 10 factors estimating sepsis were maternal age, cervicovaginitis and neonatal: fever, apneas, platelet counts, gender, bradypnea, band cells, catheter use, and birth weight.

1 December 2021 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
RSR. Sevilla‐Montoya
R. Sevilla‐Montoya
AHA. Hidalgo‐Bravo
A. Hidalgo‐Bravo
GEG. Estrada‐Gutiérrez
G. Estrada‐Gutiérrez
OVOSCAR VILLAVICENCIO-CARRISOZA
OSCAR VILLAVICENCIO-CARRISOZA
MLM. Leon‐Juarez
M. Leon‐Juarez
COCollaborators
Collaborators
Objective: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vertical transmission has been investigated extensively. Recently, the World Health Organization (WHO) published strict criteria to classify the timing of mother‐to‐child transmission of SARS‐CoV‐2 into different categories. The aim of this study was to investigate the possibility of vertical transmission in asymptomatic SARS‐CoV‐2‐positive women.Methods: Pregnant women attending for delivery at a perinatology center in Mexico City, Mexico, who had a SARS‐CoV‐2‐positive nasopharyngeal swab 24–48 h before delivery, were asymptomatic at the time of the test and had an obstetric indication for Cesarean section were eligible for inclusion in this study. Amniotic fluid was collected during Cesarean delivery, and neonatal oral and rectal swabs were collected at birth and at 24 h after birth. SARS‐CoV‐2 detection was carried out using real‐time reverse‐transcription polymerase chain reaction in all samples. Relevant medical information was retrieved from clinical records. The WHO criteria for classifying the timing of mother‐to‐child transmission of SARS‐CoV‐2 were applied to the study population.Results: Forty‐two SARS‐CoV‐2‐positive asymptomatic pregnant women fulfilled the inclusion criteria. Twenty‐five (59%) women developed mild disease after discharge. Neonatal death occurred in three (7%) cases, of which one had a positive SARS‐CoV‐2 test at birth and none had coronavirus disease 2019‐related symptoms. There were five (12%) cases with strong evidence of intrauterine transmission of SARS‐CoV‐2, according to the WHO criteria, as amniotic fluid samples and neonatal samples at birth and at 24 h after birth were positive for SARS‐CoV‐2. Our results also showed that 40–60% of infected neonates would have been undetected if only one swab (oral or rectal) was tested.Conclusion: This study contributes evidence to reinforce the potential for vertical transmission of SARS‐CoV‐2 even in asymptomatic women and highlights the importance of testing more than one neonatal sample in order to increase the detection rate of SARS‐CoV‐2 in affected cases. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Verified
Journal Article
Open access
PDF file
RJRodrigo Jiménez-Escutia
Rodrigo Jiménez-Escutia
DVDonovan Vargas-Alcantar
Donovan Vargas-Alcantar
MFMaría del Pilar Flores-Espinosa
María del Pilar Flores-Espinosa
Addy Cecilia Helguera-RepettoAddy Cecilia Helguera-Repetto
Addy Cecilia Helguera-Repetto
OVOSCAR VILLAVICENCIO-CARRISOZA
OSCAR VILLAVICENCIO-CARRISOZA
Andrea Olmos-OrtizAndrea Olmos-Ortiz
Andrea Olmos-Ortiz
Placentas from gestational diabetes mellitus (GDM) patients undergo significant metabolic and immunologic adaptations due to hyperglycemia, which results in an exacerbated synthesis of proinflammatory cytokines and an increased risk for infections. Insulin or metformin are clinically indicated for the treatment of GDM; however, there is limited information about the immunomodulatory activity of these drugs in the human placenta, especially in the context of maternal infections. Our objective was to study the role of insulin and metformin in the placental inflammatory response and innate defense against common etiopathological agents of pregnancy bacterial infections, such as E. coli and S. agalactiae, in a hyperglycemic environment. Term placental explants were cultivated with glucose (10 and 50 mM), insulin (50–500 nM) or metformin (125–500 µM) for 48 h, and then they were challenged with live bacteria (1 × 105 CFU/mL). We evaluated the inflammatory cytokine secretion, beta defensins production, bacterial count and bacterial tissue invasiveness after 4–8 h of infection. Our results showed that a GDM-associated hyperglycemic environment induced an inflammatory response and a decreased beta defensins synthesis unable to restrain bacterial infection. Notably, both insulin and metformin exerted anti-inflammatory effects under hyperglycemic infectious and non-infectious scenarios. Moreover, both drugs fortified placental barrier defenses, resulting in reduced E. coli counts, as well as decreased S. agalactiae and E. coli invasiveness of placental villous trees. Remarkably, the double challenge of high glucose and infection provoked a pathogen-specific attenuated placental inflammatory response in the hyperglycemic condition, mainly denoted by reduced TNF-α and IL-6 secretion after S. agalactiae infection and by IL-1β after E. coli infection. Altogether, these results suggest that metabolically uncontrolled GDM mothers develop diverse immune placental alterations, which may help to explain their increased vulnerability to bacterial pathogens.

21 January 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
OVOSCAR VILLAVICENCIO-CARRISOZA
OSCAR VILLAVICENCIO-CARRISOZA
ODOrly Grobeisen Duque
Orly Grobeisen Duque
AGAna Laura Garcia-Correa
Ana Laura Garcia-Correa
IMIrma Eloisa Monroy Muñoz
Irma Eloisa Monroy Muñoz
GVGraciela Villeda-Gabriel
Graciela Villeda-Gabriel
Addy Cecilia Helguera-RepettoAddy Cecilia Helguera-Repetto
Addy Cecilia Helguera-Repetto
Neonatal sepsis is a major cause of mortality in preterm infants, with Escherichia coli as one of the leading pathogens. Few studies have examined the interplay between virulence factors, resistance profiles, phylogroups, and clinical outcomes in this population. We analyzed 52 E. coli strains isolated from 49 preterm neonates diagnosed with sepsis at a tertiary-level hospital in Mexico. Strains underwent phylogenetic classification, virulence gene profiling, and antimicrobial resistance testing. PFGE was used to assess genetic relatedness and outbreak clusters. Clinical data were correlated with molecular findings. Phylogroups A and B2 accounted for 46% of strains. Phylogroup A exhibited notable virulence, with high prevalence of the pathogenicity island described in virulent extra-intestinal E. coli strains (PAI), aerobactin siderophore receptor AerJ (iutA), and yersiniabactin siderophore receptor (fyuA) genes, alongside significant resistance profiles. PFGE identified two dominating branches. Branch A, comprising phylogroups A and B2, displayed high resistance and was prevalent in the neonatal intensive care unit. Branch C, with phylogroups A and D, showed less multidrug resistance but was significantly associated with maternal chorioamnionitis. This study redefines E. coli pathogenicity in neonatal sepsis, highlighting the virulence of traditionally non-pathogenic phylogroups. High virulence strains were associated with more severe outcomes. These findings underscore the need for enhanced strategies in targeted prevention, improved diagnostics, and tailored treatments for high-risk preterm populations.

Verified
Journal Article
Open access
PDF file
Andrea Olmos-OrtizAndrea Olmos-Ortiz
Andrea Olmos-Ortiz
MHMayra Hernández-Pérez
Mayra Hernández-Pérez
MFMaría del Pilar Flores-Espinosa
María del Pilar Flores-Espinosa
GSGabriela Sedano
Gabriela Sedano
Addy Cecilia Helguera-RepettoAddy Cecilia Helguera-Repetto
Addy Cecilia Helguera-Repetto
VZVerónica Zaga-Clavellina
Verónica Zaga-Clavellina
An infectious process into the uterine cavity represents a major endangered condition that compromises the immune privilege of the maternal–fetal unit and increases the risk for preterm birth (PTB) and premature rupture of membranes (PROM). Fetal membranes are active secretors of antimicrobial peptides (AMP), which limit bacterial growth, such as Escherichia coli. Nevertheless, the antibacterial responses displayed by chorioamniotic membranes against a choriodecidual E. coli infection have been briefly studied. The objective of this research was to characterize the profile of synthesis, activity, and spatial distribution of a broad panel of AMPs produced by fetal membranes in response to E. coli choriodecidual infection. Term human chorioamniotic membranes were mounted in a two independent compartment model in which the choriodecidual region was infected with live E. coli (1 × 105 CFU/mL). Amnion and choriodecidual AMP tissue levels and TNF-α and IL-1β secretion were measured by the enzyme-linked immunosorbent assay. The passage of bacterium through fetal membranes and their effect on structural continuity was followed for 24 h. Our results showed that E. coli infection caused a progressive mechanical disruption of the chorioamniotic membranes and an activated inflammatory environment. After the challenge, the amnion quickly (2–4 h) induced production of human beta defensins (HBD)-1, HBD-2, and LL-37. Afterwards (8–24 h), the amnion significantly produced HBD-1, HBD-2, HNP-1-3, S100A7, sPLA2, and elafin, whereas the choriodecidua induced LL-37 synthesis. Therefore, we noticed a temporal- and tissue-specific pattern regulation of the synthesis of AMPs by infected fetal membranes. However, fetal membranes were not able to contain the collagen degradation or the bacterial growth and migration despite the battery of produced AMPs, which deeply increases the risk for PTB and PROM. The mixture of recombinant HBDs at low concentrations resulted in increased bactericidal activity compared to each HBD alone in vitro, encouraging further research to study AMP combinations that may offer synergy to control drug-resistant infections in the perinatal period.